Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · May 19, 2021
Trial Information
Current as of June 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called hyperviscosity syndrome (HVS) in patients with Waldenström Macroglobulinemia (WM), a type of blood cancer. HVS occurs when there is a high level of a specific protein called immunoglobulin M (IgM) in the blood, which can cause various symptoms like bleeding, fatigue, and vision problems. The goal of the study is to develop a clear way to diagnose HVS by looking at both physical signs and symptoms reported by patients, helping doctors decide when treatment is needed.
To participate in this study, patients must have a diagnosis of WM and may require treatment either for the first time or after trying other therapies. They should have a specific level of IgM in their blood and be willing to provide consent to join the trial. This research is currently recruiting participants aged 65 to 74, and both men and women are eligible. If you join, you can expect to undergo assessments to measure your symptoms and overall health related to hyperviscosity syndrome. This study aims to improve understanding and treatment of this condition, which can greatly impact patients' lives.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with WM
- • Patients that may require a first-line or subsequent-line therapy
- • patients who will require treatment initiation
- • patients with serum monoclonal component concentration greater than 15 g/L and who will underwent hyperviscosity assessment, even if hyperviscosity is not found and in the absence of other treatment criteria, no treatment is finally initiated.
- • Patients agreeing to give informed consent.
- Exclusion Criteria:
- • Patients with another chronic B-cell malignancy
- • patients with lymphoplasmacytic proliferations
- • patients with marginal zone lymphoma.
- • patients with WM and histologic transformation
- • Absence of informed consent.
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials